Amazonian plants plucked from the ground. Baseball bats emerging from trees. Chocolate chip cookie ingredients separated from the dough. They were all part of the discussion Monday as the Supreme Court grappled with the science behind Myriad Genetics Inc.'s gene-based claims – and patent law itself.
Among the thousands of interesting people who will be attending the 2013 BIO International Convention in Chicago, which kicks off one week from today, are young standouts who are already making their mark in biotech.
Biotech Supreme Court watchers are looking at the what ifs ahead of Monday's arguments in a case that could overturn 30 years of established precedent, undoing isolated DNA claims and possibly threatening thousands of patents on proteins and other compounds that could be deemed "products of nature."
The $3.77 trillion budget proposal for fiscal 2014 that the White House unveiled Wednesday offers drugmakers a mixed bag of good news and bad news in terms of tax reforms and health care spending.
The Arkansas Supreme Court is being asked to overturn the $1.2 billion penalty assessed against Janssen Pharmaceuticals Inc. in a case that could open other drugmakers to hefty penalties when the state decides FDA-approved labeling is inadequate.
An appellate court's ruling Wednesday against Pfizer Inc. paints the way forward for more racketeering claims against drugmakers who plead guilty to criminal off-label promotion charges as part of a government settlement.
Raising fees is not the way to reduce a growing backlog of requests for continued examination (RCEs), several patent attorneys told the Patent and Trademark Office (PTO) Wednesday.
Recognizing the global impact its decision could have, the Supreme Court of India denied an appeal by Novartis AG, ending the company's 15-year quest for a patent for its cancer drug Gleevec/Glivec.
Much to-do has been made about the FDA's draft guidance on developing drugs for early stage Alzheimer's disease (AD), but some people are missing the point, especially if they think the agency is "loosening" its standards for Alzheimer's treatments, according to an FDA official.